The effects of hormone replacement therapy on postmenopausal breast cancer biology and survival

Department of Surgery and the Center on Outcomes Research and Education, NorthShore University Health System, Evanston, and Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
American journal of surgery (Impact Factor: 2.36). 03/2009; 197(3):403-7. DOI: 10.1016/j.amjsurg.2008.11.014
Source: PubMed

ABSTRACT The goal of this study was to compare the characteristics of breast cancers and survival rates in HRT users versus nonusers.
Data were analyzed for 1055 patients > or = 50 years of age who had definitive therapy for breast cancer from 1994 through 2002.
There were 471 (45%) HRT users. The median age at diagnosis was 61.0 years for HRT users and 68.0 years for HRT nonusers (P < .001). HRT users more often had tumors that were <1 cm (P = .007), node negative (P = .033), and grade I (P = .016). HRT users had a decreased risk of death versus nonusers (hazard ratio = .438, 95% confidence limit = .263 to .729, P = .002).
HRT users developed breast cancer at a younger age than nonusers; HRT use was associated with the development of biologically more favorable cancers than those that developed in nonusers; and overall and disease-free survival rates were higher in HRT users than nonusers.

  • [Show abstract] [Hide abstract]
    ABSTRACT: ABSTRACT Background: Several studies report a Breast Cancer (BC) incidence decrease subsequent to the decrease in Hormone replacement therapy (HRT) use. But its magnitude and the time-lag may vary between countries. This may reflect differences in populations, previous type and prevalence of HRT use and BC screening. Aim: To review systematically studies assessing the relation between BC incidence and change of HRT use. Material and method: Descriptive analysis of the methodology of the studies including design limitations and presence of confounding factors, data sources for BC and HRT and regimens of HRT used. Results and discussion: Eighteen articles were selected. Most studies were ecological and confounding factors such as mammography screening and changes in reproductive and life style habits could not be excluded. Sources of data on BC and HRT were heterogeneous and only few data on HRT regimens used were available. Most studies concluded that the decrease in HRT use during the last decade was probably associated with a BC incidence decrease, especially for women aged 50 or more. Conclusions: Data, mostly from epidemiological studies, suggest that the BC incidence decrease can be partly attributed to the HRT use drop. Nevertheless, available studies are hampered by a number of limitations and it remains difficult to evaluate the exact impact of HRT drop on BC incidence decrease. Especially, the studies are seldom based on detailed individual data and don't provide information on used regimens, type of cancers and possible confounding factors.
    Climacteric 08/2013; 17(2). DOI:10.3109/13697137.2013.829812 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Objectives The association between pre-diagnostic hormone replacement therapy (HRT) and breast cancer specific mortality as well as potential influences from other lifestyle factors on the association was investigated. Study design: Female participants from the prospective cohort “Diet, Cancer, and Health” diagnosed with breast cancer (BC) were identified and their pre-diagnostic HRT use evaluated for association with tumour biology and breast cancer outcome in multivariate analysis. Main outcome measure: Breast cancer specific mortality Results Of the 1 212 patients originally considered 1 064 were included. Of these, 105 women died from breast cancer during a median follow-up of 6.3 years (range 0.2-14.3 years). In multivariate analyses women who used HRT at enrolment into the cohort study had 47% lower risk of dying from breast cancer as compared to women who had previously or never used HRT (adjusted HR: 0.53; 95% CI, 0.37-0.85). Pre-diagnostic HRT use was associated with smaller tumour size at the time of diagnosis and a higher frequency of receptor positive breast cancer. Paradoxically, a high pre-diagnostic intake of vitamin D supplements was associated with HRT use but also with a higher BC specific mortality (HR: 1.47; 95% CI, 1.07-2.00) Conclusions HRT-use at enrolment was associated with breast tumours of smaller size at the time of diagnosis and positive receptor status, and with a lower BC mortality. The found association between vitamin D from supplements and higher BC mortality warrants further exploration.
    Maturitas 09/2014; 79(4). DOI:10.1016/j.maturitas.2014.09.004 · 2.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Key contentHormone replacement therapy (HRT) is the most effective treatment for symptoms of estrogen deficiency. When HRT is individually tailored women gain maximum advantages and the risks are minimised.Several types and regimens of HRT and different routes of delivery exist. Results from studies using only one type and route may not therefore apply to all users.The use of HRT is an individual decision, which a woman can only make once she has been given correct information and advice from healthcare professionals.HRT should be recommended in women with premature ovarian insufficiency with advice to continue until the average age of the menopause at 51.4 years.Learning objectivesTo review the current research and the evidence on the use of HRT in women.Application of the evidence in relation to the management of the symptomatic menopausal woman.To promote confidence in prescribing HRT in most symptomatic women.To have a general overview of prescribing in women with relative contraindications.Ethical issuesThe use of HRT is a patient informed choice.Where evidence is limited and quality of life a priority, then a multidisciplinary approach may be necessary and informed written consent documented.
    The Obstetrician & Gynaecologist 12/2014; DOI:10.1111/tog.12155

Full-text (2 Sources)

Available from
Nov 4, 2014